Phenprocoumon
From Wikipedia, the free encyclopedia
|
Phenprocoumon
|
|
| Systematic (IUPAC) name | |
| 2-hydroxy-3-(1-phenylpropyl)chromen-4-one | |
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H16O3 |
| Mol. mass | 280.318 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | hepatic to inactive metabolites |
| Half life | 5 to 6 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Phenprocoumon (marketed under the brand names Marcoumar, Marcumar and Falithrom) is an anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders (thrombosis/pulmonary embolism).
[edit] External links
|
||||||||||||||||||||||||||
its new upgraded drug for anticoagulant properties and mechanism of action is unknown

